{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T08:49:33Z","timestamp":1788684573459,"version":"build-2803163510"},"reference-count":85,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Accumulating evidence indicates that diabetes is associated with increased risk of several cancers. The strongest evidence has been reported for cancers of the breast, colorectum, endometrium, liver, pancreas, and gallbladder. However, distinguishing causal relationships from associations driven by shared risk factors such as obesity, aging, and lifestyle behaviors remains challenging. Several biological mechanisms have been proposed to explain these associations. Key pathways include the effects of insulin resistance and compensatory hyperinsulinemia on mitogenic signaling pathways, including PI3K\/AKT\/mTOR and MAPK, as well as the influence of adiposity, chronic inflammation, and altered metabolic substrates on tumor initiation and progression. Hyperglycemia may also contribute by promoting tumor metabolism and cellular proliferation, although its independent contribution remains debated. These mechanisms likely interact to create a protumorigenic metabolic environment in individuals with diabetes. Obesity, which frequently co-occurs with diabetes, further amplifies these risks through altered adipokine secretion and increased estrogen production, highlighting the interrelated contributions of metabolic and hormonal factors. The relationship between diabetes and cancer has important clinical implications. Diabetes has been associated with worse cancer prognosis and higher cancer-related mortality, highlighting the importance of integrated management strategies. The impact of antihyperglycemic therapy on cancer risk and progression has been extensively studied, and ongoing research continues to evaluate potential protective or tumor-modifying effects. In this article, we summarize the epidemiologic and pathophysiologic evidence describing the relationship between diabetes and cancer and discuss strategies for risk mitigation, screening, and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                  <\/jats:sec>","DOI":"10.2337\/dbi26-0003","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T21:31:27Z","timestamp":1780781487000},"page":"1347-1358","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":2,"title":["The Link Between Diabetes and Cancer: Converging Mechanistic and Epidemiologic Evidence"],"prefix":"10.2337","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-7993","authenticated-orcid":false,"given":"Lorraine L.","family":"Lipscombe","sequence":"first","affiliation":[{"name":"Department of Medicine, Women\u2019s College Hospital 1 , Toronto, Canada"},{"name":"Department of Medicine, University of Toronto 2 , Toronto, Canada"},{"name":"ICES 3 , Toronto, Canada"},{"name":"Institute for Health Policy, Management and Evaluation, University of Toronto 4 , Toronto, Canada"},{"name":"Institute of Medical Science, University of Toronto 5 , Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameen","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Women\u2019s College Hospital 1 , Toronto, Canada"},{"name":"Institute of Medical Science, University of Toronto 5 , Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-2589","authenticated-orcid":false,"given":"Iliana C.","family":"Lega","sequence":"additional","affiliation":[{"name":"Department of Medicine, Women\u2019s College Hospital 1 , Toronto, Canada"},{"name":"Department of Medicine, University of Toronto 2 , Toronto, Canada"},{"name":"ICES 3 , Toronto, Canada"},{"name":"Institute for Health Policy, Management and Evaluation, University of Toronto 4 , Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"2026082716565646000_B1","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1158\/1055-9965.EPI-20-1245","article-title":"Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomization studies","volume":"30","author":"Pearson-Stuttard","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026082716565646000_B2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/jjco\/hyy047","article-title":"Type 1 diabetes mellitus and risk of cancer: a meta-analysis of observational studies","volume":"48","author":"Sona","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"2026082716565646000_B3","doi-asserted-by":"crossref","first-page":"800995","DOI":"10.3389\/fendo.2022.800995","article-title":"The relationship between diabetes mellitus and cancers and its underlying mechanisms","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026082716565646000_B4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/cancers15020485","article-title":"Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management","volume":"15","author":"Pati","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026082716565646000_B5","doi-asserted-by":"crossref","first-page":"1396022","DOI":"10.3389\/fendo.2024.1396022","article-title":"Effects of T2DM on cancer progression: pivotal precipitating factors and underlying mechanisms","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026082716565646000_B6","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-016-3884-9","article-title":"Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals","volume":"59","author":"Carstensen","year":"2016","journal-title":"Diabetologia"},{"key":"2026082716565646000_B7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/CEJ.0b013e32836162aa","article-title":"Breast cancer incidence before and after diagnosis of type 2 diabetes mellitus in women: increased risk in the prediabetes phase","volume":"23","author":"Onitilo","year":"2014","journal-title":"Eur J Cancer Prev"},{"key":"2026082716565646000_B8","doi-asserted-by":"crossref","first-page":"e70426","DOI":"10.1371\/journal.pone.0070426","article-title":"Increased risk of colon cancer in men in the pre-diabetes phase","volume":"8","author":"Onitilo","year":"2013","journal-title":"PLoS One"},{"key":"2026082716565646000_B9","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/cncr.30095","article-title":"The temporal relationship between diabetes and cancer: a population-based study","volume":"122","author":"Lega","year":"2016","journal-title":"Cancer"},{"key":"2026082716565646000_B10","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00125-011-2242-1","article-title":"Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias","volume":"54","author":"Johnson","year":"2011","journal-title":"Diabetologia"},{"key":"2026082716565646000_B11","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-011-2381-4","article-title":"Cancer occurrence in Danish diabetic patients: duration and insulin effects","volume":"55","author":"Carstensen","year":"2012","journal-title":"Diabetologia"},{"key":"2026082716565646000_B12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00404-016-4275-7","article-title":"The association between a history of gestational diabetes mellitus and future risk for female malignancies","volume":"295","author":"Fuchs","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"2026082716565646000_B13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jcjd.2023.12.007","article-title":"Risk of breast cancer after diabetes in pregnancy: a population-based cohort study","volume":"48","author":"Gill","year":"2024","journal-title":"Can J Diabetes"},{"key":"2026082716565646000_B14","first-page":"808","article-title":"Association between gestational diabetes mellitus and risk of overall and site-specific cancers (pancreatic, liver, thyroid, lung): a systematic review and meta-analysis","volume":"15","author":"Tian","year":"2025","journal-title":"Life (Basel)"},{"key":"2026082716565646000_B15","doi-asserted-by":"crossref","first-page":"1621932","DOI":"10.3389\/fendo.2025.1621932","article-title":"Association between gestational diabetes mellitus and risk of breast cancer: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026082716565646000_B16","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis","volume":"300","author":"Barone","year":"2008","journal-title":"JAMA"},{"key":"2026082716565646000_B17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"2026082716565646000_B18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clon.2018.01.003","article-title":"Hyperglycaemia and survival in solid tumours: a systematic review and meta-analysis","volume":"30","author":"Barua","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2026082716565646000_B19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1186\/s12885-022-10144-y","article-title":"Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis","volume":"22","author":"Ling","year":"2022","journal-title":"BMC Cancer"},{"key":"2026082716565646000_B20","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.2337\/dc20-0204","article-title":"Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people","volume":"43","author":"Ling","year":"2020","journal-title":"Diabetes Care"},{"key":"2026082716565646000_B21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dc14-1996","article-title":"Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation","volume":"38","author":"Harding","year":"2015","journal-title":"Diabetes Care"},{"key":"2026082716565646000_B22","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1093\/jnci\/djaf154","article-title":"Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults","volume":"117","author":"Liu","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026082716565646000_B23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jnci\/djy090","article-title":"Pancreatic cancer following incident diabetes in African Americans and Latinos: the multiethnic cohort","volume":"111","author":"Setiawan","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2026082716565646000_B24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1055-9965.EPI-17-1177","article-title":"Causal inference in cancer epidemiology: what is the role of Mendelian randomization?","volume":"27","author":"Yarmolinsky","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026082716565646000_B25","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1007\/s00125-020-05228-y","article-title":"Using genetics to decipher the link between type 2 diabetes and cancer: shared aetiology or downstream consequence?","volume":"63","author":"Vincent","year":"2020","journal-title":"Diabetologia"},{"key":"2026082716565646000_B26","doi-asserted-by":"crossref","first-page":"1354549","DOI":"10.3389\/or.2024.1354549","article-title":"Diabetes and cancer: a twisted bond","volume":"18","author":"Cosmin Stan","year":"2024","journal-title":"Oncol Rev"},{"key":"2026082716565646000_B27","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer--viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"2026082716565646000_B28","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2213-8587(18)30150-5","article-title":"Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment","volume":"6","author":"Pearson-Stuttard","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026082716565646000_B29","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nrc3174","article-title":"Molecular mechanisms of cancer development in obesity","volume":"11","author":"Khandekar","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2026082716565646000_B30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3109\/03014460.2010.507221","article-title":"A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"38","author":"Crowe","year":"2011","journal-title":"Ann Hum Biol"},{"key":"2026082716565646000_B31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.2009.976","article-title":"Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"302","author":"Li","year":"2009","journal-title":"JAMA"},{"key":"2026082716565646000_B32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.orcp.2019.03.006","article-title":"Circulating adipokines and risk of obesity related cancers: a systematic review and meta-analysis","volume":"13","author":"Yoon","year":"2019","journal-title":"Obes Res Clin Pract"},{"key":"2026082716565646000_B33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1067\/msy.2003.267","article-title":"Is obesity an inflammatory disease?","volume":"134","author":"Ramos","year":"2003","journal-title":"Surgery"},{"key":"2026082716565646000_B34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/dom.12124","article-title":"Diabetes and cancer: two diseases with obesity as a common risk factor","volume":"16","author":"Garg","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2026082716565646000_B35","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/dme.13031","article-title":"Relationship between HbA1c and cancer in people with or without diabetes: a systematic review","volume":"33","author":"Hope","year":"2016","journal-title":"Diabet Med"},{"key":"2026082716565646000_B36","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"2026082716565646000_B37","doi-asserted-by":"crossref","first-page":"e27074","DOI":"10.1371\/journal.pone.0027074","article-title":"High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR","volume":"6","author":"Han","year":"2011","journal-title":"PLoS One"},{"key":"2026082716565646000_B38","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.2337\/diabetes.53.12.3226","article-title":"Hyperglycemia regulates hypoxia-inducible factor-1\u03b1 protein stability and function","volume":"53","author":"Catrina","year":"2004","journal-title":"Diabetes"},{"key":"2026082716565646000_B39","first-page":"1279","article-title":"Hyperglycemia enhances the invasive and migratory activity of pancreatic cancer cells via hydrogen peroxide","volume":"25","author":"Li","year":"2011","journal-title":"Oncol Rep"},{"key":"2026082716565646000_B40","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/jnci\/92.18.1472","article-title":"Role of the insulin-like growth factor family in cancer development and progression","volume":"92","author":"Yu","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2026082716565646000_B41","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1172\/JCI137556","article-title":"Hypoxia-inducible factors and diabetes","volume":"130","author":"Gunton","year":"2020","journal-title":"J Clin Invest"},{"key":"2026082716565646000_B42","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/mnfr.201500759","article-title":"Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: an emerging biological factor in cancer onset and progression","volume":"60","author":"Lin","year":"2016","journal-title":"Mol Nutr Food Res"},{"key":"2026082716565646000_B43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/13813450801954451","article-title":"Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies","volume":"114","author":"Pisani","year":"2008","journal-title":"Arch Physiol Biochem"},{"key":"2026082716565646000_B44","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/curroncol32090477","article-title":"The role of insulin resistance in cancer","volume":"32","author":"Subedi","year":"2025","journal-title":"Curr Oncol"},{"key":"2026082716565646000_B45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ijc.30729","article-title":"Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: a population-based observational study","volume":"141","author":"Tsujimoto","year":"2017","journal-title":"Int J Cancer"},{"key":"2026082716565646000_B46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbrc.2023.01.061","article-title":"Insulin promotes the proliferation and migration of pancreatic cancer cells by up-regulating the expression of PLK1 through the PI3K\/AKT pathway","volume":"648","author":"Wu","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"2026082716565646000_B47","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.7150\/ijbs.27173","article-title":"The PI3K\/AKT pathway in obesity and type 2 diabetes","volume":"14","author":"Huang","year":"2018","journal-title":"Int J Biol Sci"},{"key":"2026082716565646000_B48","first-page":"493","article-title":"Insulin signaling network in cancer","volume":"51","author":"Ray","year":"2014","journal-title":"Indian J Biochem Biophys"},{"key":"2026082716565646000_B49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fendo.2019.00481","article-title":"Insulin enhances migration and invasion in prostate cancer cells by up-regulation of FOXC2","volume":"10","author":"Sarkar","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026082716565646000_B50","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/diagnostics14192132","article-title":"The interlinking metabolic association between type 2 diabetes mellitus and cancer: molecular mechanisms and therapeutic insights","volume":"14","author":"Asiri","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026082716565646000_B51","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.tem.2010.06.007","article-title":"The proliferating role of insulin and insulin-like growth factors in cancer","volume":"21","author":"Gallagher","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"2026082716565646000_B52","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1470-2045(10)70095-4","article-title":"Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies","volume":"11","author":"Endogenous Hormones and Breast Cancer Collaborative Group","year":"2010","journal-title":"Lancet Oncol"},{"key":"2026082716565646000_B53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/369414a0","article-title":"A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis","volume":"369","author":"Christofori","year":"1994","journal-title":"Nature"},{"key":"2026082716565646000_B54","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/er.2008-0047","article-title":"Insulin receptor isoforms and insulin receptor\/insulin-like growth factor receptor hybrids in physiology and disease","volume":"30","author":"Belfiore","year":"2009","journal-title":"Endocr Rev"},{"key":"2026082716565646000_B55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-006-9471-x","article-title":"Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer","volume":"106","author":"Mulligan","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"2026082716565646000_B56","doi-asserted-by":"crossref","first-page":"109060","DOI":"10.1016\/j.jdiacomp.2025.109060","article-title":"Dietary factors and cancer outcomes in individuals with type 2 diabetes: a systematic review and meta-analysis of prospective observational studies","volume":"39","author":"Barbaresko","year":"2025","journal-title":"J Diabetes Complications"},{"key":"2026082716565646000_B57","doi-asserted-by":"crossref","first-page":"e077310","DOI":"10.1136\/bmj-2023-077310","article-title":"Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses","volume":"384","author":"Lane","year":"2024","journal-title":"BMJ"},{"key":"2026082716565646000_B58","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3390\/nu11112673","article-title":"A review of the in vivo evidence investigating the role of nitrite exposure from processed meat consumption in the development of colorectal cancer","volume":"11","author":"Crowe","year":"2019","journal-title":"Nutrients"},{"key":"2026082716565646000_B59","first-page":"e96173","article-title":"Navigating evidence on ultra-processed foods and cancer: a narrative review","volume":"17","author":"Vithayathil","year":"2025","journal-title":"Cureus"},{"key":"2026082716565646000_B60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00125-019-04995-7","article-title":"Breast, cervical and colorectal cancer screening in adults with diabetes: a systematic review and meta-analysis","volume":"63","author":"Bhatia","year":"2020","journal-title":"Diabetologia"},{"key":"2026082716565646000_B61","doi-asserted-by":"crossref","first-page":"1698850","DOI":"10.3389\/fendo.2025.1698850","article-title":"Risk factors and early prediction of pancreatic cancer among patients with diabetes mellitus: a systematic review and meta-analysis","volume":"16","author":"Cong","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026082716565646000_B62","doi-asserted-by":"crossref","first-page":"e70104","DOI":"10.1002\/edm2.70104","article-title":"Intentional weight loss and associated cancer incidence among people with overweight or obesity: a systematic literature review","volume":"8","author":"Liao","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"2026082716565646000_B63","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13058-015-0611-2","article-title":"Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence","volume":"17","author":"Bronsveld","year":"2015","journal-title":"Breast Cancer Res"},{"key":"2026082716565646000_B64","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00125-009-1453-1","article-title":"Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group","volume":"52","author":"Colhoun","year":"2009","journal-title":"Diabetologia"},{"key":"2026082716565646000_B65","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"key":"2026082716565646000_B66","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00125-009-1418-4","article-title":"Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study","volume":"52","author":"Hemkens","year":"2009","journal-title":"Diabetologia"},{"key":"2026082716565646000_B67","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00125-009-1444-2","article-title":"Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden","volume":"52","author":"Jonasson","year":"2009","journal-title":"Diabetologia"},{"key":"2026082716565646000_B68","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2337\/dc13-1468","article-title":"The association of basal insulin glargine and\/or n-3 fatty acids with incident cancers in patients with dysglycemia","volume":"37","author":"Bordeleau","year":"2014","journal-title":"Diabetes Care"},{"key":"2026082716565646000_B69","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/1753-0407.12435","article-title":"Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: a systematic review","volume":"9","author":"Chen","year":"2017","journal-title":"J Diabetes"},{"key":"2026082716565646000_B70","doi-asserted-by":"crossref","first-page":"874344","DOI":"10.3389\/fendo.2022.874344","article-title":"Sulfonylurea and cancer risk among patients with type 2 diabetes: a population-based cohort study","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026082716565646000_B71","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"key":"2026082716565646000_B72","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1158\/1055-9965.EPI-14-0327","article-title":"The effect of metformin on mortality following cancer among patients with diabetes","volume":"23","author":"Lega","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026082716565646000_B73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12967-023-04263-8","article-title":"Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing","volume":"21","author":"Hua","year":"2023","journal-title":"J Transl Med"},{"key":"2026082716565646000_B74","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"key":"2026082716565646000_B75","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"key":"2026082716565646000_B76","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s13340-018-0360-4","article-title":"Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies","volume":"10","author":"Meht\u00e4l\u00e4","year":"2018","journal-title":"Diabetol Int"},{"key":"2026082716565646000_B77","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s43018-025-01110-1","article-title":"Glucagon-like peptide-1 medicines and cancer","volume":"7","author":"Yabut","year":"2026","journal-title":"Nat Cancer"},{"key":"2026082716565646000_B78","doi-asserted-by":"crossref","first-page":"e3004","DOI":"10.1002\/dmrr.3004","article-title":"Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis","volume":"34","author":"Overbeek","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"2026082716565646000_B79","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"57","author":"Dicembrini","year":"2020","journal-title":"Acta Diabetol"},{"key":"2026082716565646000_B80","doi-asserted-by":"crossref","DOI":"10.1002\/oby.24366","article-title":"Association of glucagon-like peptide-1 receptor agonists with cancer risk in older adults with type 2 diabetes","author":"Lu","year":"2025","journal-title":"Obesity (Silver Spring)."},{"key":"2026082716565646000_B81","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026082716565646000_B82","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13300-014-0053-3","article-title":"Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus","volume":"5","author":"Reilly","year":"2014","journal-title":"Diabetes Ther"},{"key":"2026082716565646000_B83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2014.09.018","article-title":"Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin","volume":"224","author":"De Jonghe","year":"2014","journal-title":"Chem Biol Interact"},{"key":"2026082716565646000_B84","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"2026082716565646000_B85","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13098-025-01898-z","article-title":"Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis","volume":"17","author":"Hajishah","year":"2025","journal-title":"Diabetol Metab Syndr"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/75\/8\/1347\/873480\/dbi260003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/75\/8\/1347\/873480\/dbi260003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:57:13Z","timestamp":1787864233000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/8\/1347\/169163\/The-Link-Between-Diabetes-and-Cancer-Converging"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":85,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,6,6]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi26-0003","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}